Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

In this large-scale cross-sectional study, we evaluated disease-free survival (DFS), overall survival (OS), and clinicopathological characteristics of BC patients from 1991 to 2022, retrospectively. We recruited patients referred to the Cancer Research Center in Tehran, Iran, and their HER2 status, which is classified as HER2-low, HER2-positive, or HER2-negative, was obtained from prospectively maintained registries. we aimed to dive more deeply into the clinicopathological characteristics and survival features of HER2-low breast cancer patients and campared it with HER2-negative and HER2-positive groups.

Question 1: Is HER2-low breast cancer (BC) a new subtype in the standard classification of BCs? Question 2: How is the DFS and OS rate of HER2-low breast cancer patients in comparison with HER2-negative and HER2-positive groups?

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HER2 Low Breast Carcinoma Breast Diseases Breast Neoplasms Neoplasms Neoplasms by Site Skin Diseases Skin and Connective Tissue Diseases

Sex eligibility

Female

Study type

Observational

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All breast cancer patients with human epidermal growth factor receptor 2 (HER2) status in the database of the Cancer Research Center (CRC),from April 1991 to March 2022

Exclusion criteria

The male gender Patients with indeterminate or missing HER2 status, or patients with missing DFS and OS information

Treatment and study plan

immunohistochemistry (IHC) and in situ hybridization (ISH) Test

Diagnostic Test

These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors

Primary outcomes

HER2-low OS

Time frame: 38 months

HER2-low status had the highest survival rate.
HER2-low DFS

Time frame: 33 months

HER2-low status had the highest DFS.

Sponsors and collaborators

Lead sponsor

Mahdis Bayat

Other

Registry information

Official study title

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients; a Cross-Sectional Study

Important dates

Study start: 1991
Primary completion: 2022
Study completion: 2022
First posted: Mar 3, 2023
Registry last updated: Mar 3, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Recruiting